bsd8k091108.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): September 11,
2008
BSD
MEDICAL CORPORATION
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-10783
|
75-1590407
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
2188
West 2200 South
Salt
Lake City, Utah 84119
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (801) 972-5555
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events.
FDA
510(k) Marketing Clearance Letter
On
September 11, 2008, BSD Medical Corporation (“BSD”) issued a press release
announcing that it received a letter from the United States Food and Drug
Administration granting BSD 510(k) clearance to market its MicroThermX-100
Microwave Ablation System. A copy of the press release is attached as
Exhibit 99.1 and incorporated by reference herein.
Stock
Purchase Agreement
Based on
a prior agreement, the company executives and directors, Hyrum A. Mead and Paul
F. Turner, have agreed, subject to the satisfaction of certain closing
conditions, to exercise stock options and sell up to an aggregate of four
hundred fifty thousand shares from among their vested stock options in an
off-market transaction to institutional investors at this time. The
sale is subject to certain closing conditions, including (1) the achievement of
Food and Drug Administration marketing clearance for the company’s
MicroThermX®-100, and (2) requirements relating to the trading volume and share
price of BSD Medical’s common stock. More than half of the stock
options anticipated for use in this off-market sale have been held for
approximately nine years since granting, and are due to expire in between
approximately eleven and sixteen months. Together Mr. Turner and Mr.
Mead beneficially own approximately 2.9 million shares in the form of common
stock and stock options. BSD Medical has traditionally used stock
options as a primary means of recognizing its employees and executives for their
contributions to the company.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: September
11, 2008
|
|
BSD
MEDICAL CORPORATION
|
|
|
|
By:
|
/s/ Hyrum A. Mead
|
|
|
|
Name:
|
Hyrum
A. Mead
|
|
|
|
Title:
|
President
and Chief Executive Officer
|
|
EXHIBIT
INDEX